Free Trial
NASDAQ:RVPH

Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis

Reviva Pharmaceuticals logo
$0.49 +0.13 (+35.12%)
Closing price 10/2/2025 04:00 PM Eastern
Extended Trading
$0.52 +0.04 (+7.63%)
As of 08:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Reviva Pharmaceuticals Stock (NASDAQ:RVPH)

Advanced

Key Stats

Today's Range
$0.37
$0.53
50-Day Range
$0.27
$0.54
52-Week Range
$0.25
$4.28
Volume
41.54 million shs
Average Volume
7.12 million shs
Market Capitalization
$33.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.86
Consensus Rating
Buy

Company Overview

Reviva Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
75th Percentile Overall Score

RVPH MarketRank™: 

Reviva Pharmaceuticals scored higher than 75% of companies evaluated by MarketBeat, and ranked 278th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Reviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    Reviva Pharmaceuticals has a consensus price target of $4.86, representing about 895.7% upside from its current price of $0.49.

  • Amount of Analyst Coverage

    Reviva Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Reviva Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($0.97) to ($0.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Reviva Pharmaceuticals is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Reviva Pharmaceuticals is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Reviva Pharmaceuticals has a P/B Ratio of 24.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Reviva Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    18.76% of the outstanding shares of Reviva Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Reviva Pharmaceuticals has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Reviva Pharmaceuticals has recently decreased by 0.76%, indicating that investor sentiment is improving.
  • Dividend Yield

    Reviva Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Reviva Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    18.76% of the outstanding shares of Reviva Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Reviva Pharmaceuticals has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Reviva Pharmaceuticals has recently decreased by 0.76%, indicating that investor sentiment is improving.
  • News Sentiment

    Reviva Pharmaceuticals has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Reviva Pharmaceuticals this week, compared to 1 article on an average week.
  • Search Interest

    53 people have searched for RVPH on MarketBeat in the last 30 days. This is an increase of 165% compared to the previous 30 days.
  • MarketBeat Follows

    Only 10 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    27.18% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    63.18% of the stock of Reviva Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Reviva Pharmaceuticals' insider trading history.
Receive RVPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RVPH Stock News Headlines

Chardan Capital Initiates Coverage on Reviva Pharmaceuticals (NASDAQ:RVPH)
Stunning new initiative unfolding in the White House?
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.tc pixel
Reviva Pharmaceuticals Amends Bylaws to Ease Quorum
Top 3 Health Care Stocks That May Explode In September
See More Headlines

RVPH Stock Analysis - Frequently Asked Questions

Reviva Pharmaceuticals' stock was trading at $1.81 at the beginning of the year. Since then, RVPH stock has decreased by 73.0% and is now trading at $0.4878.

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) announced its quarterly earnings results on Thursday, August, 14th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.03.

Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Reviva Pharmaceuticals investors own include Sangamo Therapeutics (SGMO), Salesforce (CRM), Adobe (ADBE), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Airbnb (ABNB) and Marvell Technology (MRVL).

Company Calendar

Last Earnings
8/14/2025
Today
10/03/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:RVPH
CIK
1742927
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

High Price Target
$11.00
Low Price Target
$2.00
Potential Upside/Downside
+895.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.65)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$29.92 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-259.17%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.90
Quick Ratio
0.90

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.02 per share
Price / Book
24.39

Miscellaneous

Outstanding Shares
69,340,000
Free Float
50,491,000
Market Cap
$33.82 million
Optionable
Optionable
Beta
-0.08

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:RVPH) was last updated on 10/3/2025 by MarketBeat.com Staff
From Our Partners